A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

被引：2

作者：

Kotb, Rami ^{[1
]}

Gul, Engin ^{[2
]}

Reece, Donna E. ^{[3
,4
]}

机构：

[1] Canc Care Manitoba, Winnipeg, MB, Canada

[2] Canadian Myeloma Res Grp, Toronto, ON, Canada

[3] Canadian Myeloma Res Grp Formerly MCRN, Toronto, ON, Canada

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-15363

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4767

引用

页数：3

共 50 条

[1] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob P.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Spillane, Kerry
LaStofka, Brenton
Rosenblatt, Jacalyn
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[2] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
O'Donnell, Elizabeth K.
Mo, Clifton C.
Nadeem, Omar
Yee, Andrew J.
Branagan, Andrew R.
Laubach, Jacob
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Rosenblatt, Jacalyn
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2022, 140 : 7282 - 7283
[3] A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob
Rosenblatt, Jacalyn
Horick, Nora
Richardson, Paul G.
Raje, Noopur
Cirstea, Diana
BLOOD, 2023, 142
[4] IFM guidelines on induction and maintenance for patients with newly diagnosed transplant eligible multiple myeloma
Macro, Margaret
HEMATOLOGIE, 2019, 25 (01): : 30 - 40
[5] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[6] A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
Terpos, Evangelos
Kastritis, Efstathios
Symeonidis, Argiris
Pouli, Anastasia
Delimpasi, Sosana
Katodritou, Eirini
Hatzimichael, Eleftheria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Manousou, Kyriaki
Gavriatopoulou, Maria
Dimopoulos, Meletios A.
BLOOD, 2023, 142
[7] Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Badros, Ashraf
Foster, Laahn
Anderson Jr, Larry D.
Chaulagain, Chakra P.
Pettijohn, Erin
Cowan, Andrew J.
Costello, Caitlin
Larson, Sarah
Sborov, Douglas W.
Shain, Kenneth H.
Silbermann, Rebecca
Shah, Nina
Chung, Alfred
Krevvata, Maria
Pei, Huiling
Patel, Sharmila
Khare, Vipin
Cortoos, Annelore
Carson, Robin
Lin, Thomas S.
Voorhees, Peter
BLOOD, 2025, 145 (03) : 300 - 310
[8] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Nievergall, Eva
Fenk, Roland
Bertsch, Uta
Tichy, Diana
Besemer, Britta
Duerig, Jan
Schroers, Roland
Metzler, Ivana V.
Haenel, Mathias
Mann, Christoph
Asemissen, Anne-Marie
Heilmeier, Bernhard
Huhn, Stefanie
Kriegsmann, Katharina
Weinhold, Niels
Luntz, Steffen P.
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Khandanpour, Cyrus
Knauf, Wolfgang
Munder, Markus
Geer, Thomas
Riesenberg, Hendrik
Thomalla, Joerg
Hoffmann, Martin
Raab, Marc-Steffen
Salwender, Hans
Weisel, Katja
BLOOD, 2021, 138
[9] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
Berdeja, Jesus G.
Gregory, Tara K.
Kambhampati, Suman
Anz, Bertrand M., III
Tarantolo, Stefano R.
Meluch, Anthony A.
Matous, Jeffrey V.
BLOOD, 2019, 134
[10] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kohmei Kubo
Mitsuo Hori
Kensuke Ohta
Hiroshi Handa
Kiyohiko Hatake
Morio Matsumoto
Shotaro Hagiwara
Kazuteru Ohashi
Chiaki Nakaseko
Kenshi Suzuki
Shigeki Ito
Gen Kinoshita
Suresh G. Shelat
Masafumi Miyoshi
Naoki Takezako
International Journal of Hematology, 2020, 111 : 65 - 74

← 1 2 3 4 5 →